LG to develop a new modified osteoarthritis drug.

LG Life Science has succeeded in developing Hyruan plus, a degenerative osteoarthritis drug having 6 months to one year sustained relieving effects only by 3 times administration, at about 4 billion won of investment for the R&D over 6 years.

The company announced on Aug. 30 that the drug will be commercially available from Sept. 1 for the treatment of knee arthritis.

Hyruan plus contain...